GlassScriptPhysician profile
Jennifer Z Cooper
NPI 1619918356
$2,708.65
in general payments reported to CMS, 2019-2025
27 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 80% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $100 · 2021: $34.33 · 2022: $163 · 2023: $214 · 2024: $674 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,195 · Education: $22.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.88 |
| Education | $22.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $608.52 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $322.45 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.02 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $224.42 | 2019-2025 | |
| Lilly USA, LLC | $189.42 | 2022-2025 | Taltz, Ebglyss |
| Revance Therapeutics, INC. | $187.84 | 2024 | Daxxify |
| Pfizer INC. | $159.47 | 2022-2025 | |
| Galderma Laboratories, L.P. | $159.30 | 2019-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $147.66 | 2023-2025 | Odomzo, Blu-U |
| Leo Pharma INC. | $42.46 | 2022-2025 | Adbry |
| Incyte Corporation | $39.19 | 2022-2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $36.42 | 2024-2025 | Ycanth |
| Organon LLC | $35.84 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.17 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.36 | 2025 | Cabtreo, Jublia, Siliq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.88 | 2024-2025 | |
| Prugen, INC. Pharmaceuticals | $28.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.32 | 2025 | Sotyktu |
| Sandoz INC. | $21.67 | 2019 | |
| Nabriva Therapeutics, Plc | $21.45 | 2021 | |
| Journey Medical Corporation | $20.75 | 2025 | |
| Almirall LLC | $19.33 | 2025 | Klisyri |
| Encore Dermatology INC. | $18.15 | 2019 | |
| Mimedx Group, INC. | $18.00 | 2024 | |
| Smith+Nephew, INC. | $17.32 | 2025 | Collagenase Santyl |
| Dermavant Sciences, INC. | $14.74 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $14.68 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.